Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$0.82 - $1.44 $150,045 - $263,494
182,982 Added 146.34%
308,020 $320,000
Q1 2024

May 15, 2024

BUY
$1.17 - $1.94 $39,733 - $65,882
33,960 Added 37.29%
125,038 $182,000
Q4 2023

Feb 13, 2024

SELL
$1.02 - $1.47 $18,426 - $26,555
-18,065 Reduced 16.55%
91,078 $117,000
Q3 2023

May 14, 2024

BUY
$0.93 - $1.38 $16,800 - $24,929
18,065 Added 19.83%
109,143 $134,000
Q3 2023

Nov 14, 2023

BUY
$0.93 - $1.38 $45,259 - $67,159
48,666 Added 80.47%
109,143 $134,000
Q2 2023

May 14, 2024

SELL
$1.11 - $2.05 $11,102 - $20,504
-10,002 Reduced 14.19%
60,477 $74,000
Q2 2023

Aug 14, 2023

SELL
$1.11 - $2.05 $11,102 - $20,504
-10,002 Reduced 14.19%
60,477 $74,000
Q1 2023

May 14, 2024

BUY
$1.63 - $2.02 $66,492 - $82,401
40,793 Added 137.41%
70,479 $136,000
Q1 2023

May 11, 2023

BUY
$1.63 - $2.02 $66,492 - $82,401
40,793 Added 137.41%
70,479 $136,000
Q4 2022

May 14, 2024

BUY
$1.68 - $3.7 $8,428 - $18,562
5,017 Added 20.34%
29,686 $54,000
Q4 2022

Feb 13, 2023

BUY
$1.68 - $3.7 $8,428 - $18,562
5,017 Added 20.34%
29,686 $54,000
Q3 2022

May 14, 2024

SELL
$3.43 - $4.01 $11,294 - $13,204
-3,293 Reduced 11.78%
24,669 $90,000
Q3 2022

Nov 10, 2022

SELL
$3.43 - $4.01 $11,294 - $13,204
-3,293 Reduced 11.78%
24,669 $90,000
Q2 2022

May 14, 2024

SELL
$1.76 - $3.82 $111,084 - $241,103
-63,116 Reduced 69.3%
27,962 $102,000
Q2 2022

Aug 15, 2022

SELL
$1.76 - $3.82 $111,812 - $242,684
-63,530 Reduced 69.44%
27,962 $102,000
Q1 2022

May 16, 2022

BUY
$1.77 - $2.93 $64,027 - $105,989
36,174 Added 65.39%
91,492 $226,000
Q4 2021

Feb 14, 2022

BUY
$1.55 - $3.1 $38,967 - $77,934
25,140 Added 83.31%
55,318 $90,000
Q3 2021

Nov 10, 2021

BUY
$2.35 - $3.16 $70,918 - $95,362
30,178 New
30,178 $91,000

Others Institutions Holding OPTN

About OptiNose, Inc.


  • Ticker OPTN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 83,277,504
  • Market Cap $31.6M
  • Description
  • OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting cort...
More about OPTN
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.